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Open access under CC BYEvaluation of the skin irritancy and corrosivity potential of an ingredient is a necessity in the safety
assessment of cosmetic ingredients. To date, there are two formally validated alternatives to the rabbit
Draize test for skin corrosivity in place, namely the rat skin transcutaneous electrical resistance (TER)
assay and the Human Skin Model Test using EpiSkinTM, EpiDermTM and SkinEthicTM reconstructed human
epidermal equivalents. For skin irritation, EpiSkinTM, EpiDermTM and SkinEthicTM are validated as stand-
alone test replacements for the rabbit Draize test. Data from these tests are rarely considered in isolation
and are evaluated in combination with other factors to establish the overall irritating or corrosive poten-
tial of an ingredient. In light of the deadlines established in the Cosmetics Directive for cessation of ani-
mal testing for cosmetic ingredients, a COLIPA scientiﬁc meeting was held in Brussels on 30th January,
2008 to review the use of alternative approaches and to set up a decision tree approach for their integra-
tion into tiered testing strategies for hazard and safety assessment of cosmetic ingredients and their use
in products. In conclusion, the safety assessments for skin irritation/corrosion of new chemicals for use in
cosmetics can be conﬁdently accomplished using exclusively alternative methods.
 2009 Elsevier Inc. Open access under CC BY-NC-ND license. ).
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-NC-ND license. 1. Introduction
Skin irritation is deﬁned as reversible damage of the skin fol-
lowing the application of a test substance for up to 4 h (Scientiﬁc
Committee on Consumer Products (SCCP, 2006)).1 By contrast, skin
corrosion is deﬁned as ‘‘irreversible damage to the skin, namely vis-
ible necrosis through the epidermis and into the dermis, following
the application of a test substance for the duration period of 3 min
up to 4 h (Organisation for Economic Co-operation and Development
(OECD) Test Guideline (TG) 404). The potential of chemicals to cause
acute skin irritation must be assessed as part of a basic toxicology
program. Historically, the evaluation of the potential of a chemical
to produce skin irritation has been carried out using the Draize skin
irritation test in rabbits according to OECD TG 404 and Method B.4 of
Annex V to Directive 67/548/EEC (OECD TG 404, 2002; EU, 1967)
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2008/EC (‘‘EU–GHS” (Globally Harmonised System)) and 440/2008/
EC on test methods (EU, 2008a,b)). The chemical is applied to the
shaved area of skin and the appearance of oedema and/or erythema
is determined up to 72 h after application. Despite the universal
acceptance of this assay, the correlation between animal and human
irritancy has come under question since there have been some cases
where chemicals have been misclassiﬁed using in vivo rabbit data
(Basketter et al., 1999; York et al., 1996). The main reason for the dis-
crepancy is thought to be related to a higher susceptibility of the
rabbit to skin reactions, possibly due to differences in skin structure
between humans and rabbits.
The SCCP is the committee which provides the European Com-
mission with scientiﬁc opinions on the safety of non-food con-
sumer products, including cosmetics and therefore, alternative
methods must also meet their acceptance criteria. The European
Centre for the Validation of Alternative Methods (ECVAM), which
is independent from the SCCP, was set up to ensure that alternative
methods meet both scientiﬁc and regulatory approval. The accep-
tance of the methods depends on their validation as well as their
long-term reproducibility and consistency (Rispin et al., 2004). A
number of alternative assays have been developed to determine
the skin irritation potential of chemicals but the most signiﬁcant
milestone was the recent acceptance by the ECVAM Scientiﬁc Advi-
sory Committee (ESAC) of the use of the EpiSkinTM reconstructed
human epidermis (RHE), EpiDermTM skin irritation test (SIT) and
SkinEthicTM RHE in vitro skin models as validated stand-alone
replacements for the rabbit Draize test, distinguishing between
skin irritating (R38, similar to GHS Category 2) and non-irritating
(no-label) chemicals (ESAC, 2008).
On 11 March 2009, two bans entered into force concerning ani-
mal testing related to cosmetics products in the European Union.
Both were decided in 2003 in the context of the 7th amendment
to the Cosmetics Directive (EU, 1976), which, amongst other pur-
poses, aims at ensuring the safety of ingredients used in cosmetic
products. A ﬁrst ban concerns animal testing itself to assess the
safety of ingredients. A second ban prohibits the sale of cosmetic
products containing ingredients tested on animals. This ban is pro-
gressive, until it becomes a complete ban in March 2013 taking
into account scientiﬁc progress being made regarding repeat dose
tests for which alternative methods do not yet exist. The impact of
the ban on the use of alternative assays to replace animal tests for
the assessment of skin irritation after March 2009 was analysed at
a COLIPA (The European Cosmetics Association) scientiﬁc meeting
organised by its Safety Assessment and Skin Tolerance Project
Teams in Brussels on 29th January, 2008. Participants included
representatives from a number of cosmetic companies. Decision
tree approaches to safety assessment of chemicals used inTable 1
Overview of alternative skin corrosion assays and their application.
Assay Evaluation end point Chemica
practices
Rat skin transcutaneous electrical
resistance (TER) test
Barrier function. Reduction in the TER Identiﬁe
liquids,
product
In vitro reconstituted human
epidermal (RHE) skin corrosion
models e.g., EpiSkinTM,
EpiDermTM, SkinEthicTM, EST-
1000TM
MTT metabolism is measured as a
marker of skin viability
Identiﬁe
chemica
plates
Reconstituted membrane barrier
test: the CorrositexTM membrane
barrier test
Penetration of test substances
through a hydrogenated collagen
matrix (biobarrier) causing a colour
change in the buffer below
Identiﬁe
predictiv
of chem
qualiﬁed
a Original references and reviews of different models for skin corrosion are cited.cosmetics were developed based on the discussions held during
the workshop.
2. Results and discussion
2.1. Current alternative approaches to the assessment of skin irritation
Current safety assessment practice makes routine use of inte-
grated testing strategies based on a Weight of Evidence (WoE) ap-
proach. WoE approaches have been in use for long and have also
been investigated by ECVAM in the context of validation (Balls
et al., 2006). The principle is that all available information is con-
sidered in the assessment, in this case of skin irritation. Such infor-
mation may include, for example:
 Physicochemical properties.
 In silico methods.
 Historical in vivo animal data (including dermal toxicity data,
data from skin sensitisation studies).
 In vitro data.
 Human data (clinical and post-market surveillance/history of
safe use).
 Exposure.2.2. Alternative in vitro approaches already applicable for safety
assessment
Tables 1 and 2 list some of the alternative skin models to iden-
tify skin corrosives (Table 1) and irritants (Table 2), together with a
brief description of the assays and the information that is obtained
from them. In vitro methods for the assessment of corrosivity are
already accepted and formally established as OECD guidelines for
long and data from such assays have clearly their role in the testing
strategy for skin irritation. Since the main focus of our investiga-
tion is the assessment of skin irritation, we concentrate here on as-
says for the assessment of skin irritation. Keratinocytes play an
important role in the initiation, modulation and regulation of skin
irritation (Coquette et al., 2000), therefore, they have been central
to the development of in vitro models to evaluate this effect. In
contrast to some of the monolayer cell models, RHE models have
a functional stratum corneum and can therefore be used to test
neat (hydrophilic and hydrophobic) chemicals added directly to
the stratum corneum. One main difference between the RHE mod-
els and normal human skin is the rate of penetration of chemical
into the skin, which are higher in RHE skin equivalents than in hu-
man epidermis (Schäfer-Korting et al., 2008). This difference gives
rise to a higher sensitivity of the RHE models, however, this can be
considered to be an advantage when testing mild irritants (Perkinsl class applicability based on current
and literature
Referencea
s corrosives and non-corrosives. Solids,
and emulsions of any chemical or
class
Oliver et al. (1986), Fentem et al.
(1998), Grindon et al. (2007)
s corrosives and non-corrosives. Avoid
ls that react with the trans-well plastic
Kaufmann et al. (2000), Faller et al.
(2002), Hoffman et al. (2005);
www.cellsystems.de; Spielmann et al.
(2007), Grindon et al. (2007)
s corrosives and non-corrosives. Overall
ity of this model is low and the number
icals used in cosmetics which are
for testing using this assay are limited
Stobbe et al. (2003), Grindon et al.
(2007)
Table 2
Overview of alternative skin irritation assays and their application.
Assay Evaluation end points
which can be measured
Applicability based on current practices and literaturea Referenceb
Irritancy range detecteda Chemical class
EpiSkinTM model Viability measured by
MTT metabolism, cytokine
release e.g., IL-1a
Irritants and non-irritants A diverse group of chemicals of different
physical forms, including organic acids,
organic bases, neutral organics, inorganic
acids, inorganic bases, inorganic salts,
electrophiles, phenols and soaps/
surfactants Fentem et al. (1998)
Williams and Kupper (1996),
Spielmann et al. (2007), Coquette et al.
(2003, 2005), Welss et al. (2004);
www.invitroskin.com
EpiDermTM model Viability measured by
MTT metabolism, cytokine
release e.g., IL-1a
Irritants and non-irritants A diverse group of chemicals with varying
physicochemical properties
Faller et al. (2002), Spielmann et al.
(2007); www.mattek.com
SkinEthicTM RHE
model
Viability measured by
MTT metabolism, cytokine
release e.g., IL-1a, tissue
histology
Irritants and non-irritants.
Including IL-8 can help to
discriminate between irritant and
sensitizing chemicals
A diverse group of chemicals with varying
physicochemical properties
Kandárová et al. (2004, 2006), Tornier
et al. (2006), Coquette et al. (2003);
www.skinethic.com
Prediskin Viability measured by
MTT metabolism, tissue
histology
Irritants and non-irritants Not deﬁned due to low predictivity www.biopredic.com
Mouse skin
integrity
function test
(SIFT) (ex-vivo)
Trans-epidermal water
loss, electrical resistance
Low predictive power Not deﬁned due to low predictivity Heylings et al. (2001, 2003), Spielmann
et al. (2007)
Cultured
keratinocytes
Release of cytokines e.g.,
IL-1a and TNF-a
Irritants and non-irritants. The
lack of a stratum corneum may
result in high sensitivity and over-
predict the irritation potential
Avoid poorly water-soluble chemicals Spiekstra et al. (2005), DeLeo et al.
(1996), Gueniche and Ponec (1993),
Müller-Decker et al. (1994), Jacobs
et al. (1989), van de Sandt et al. (1999)
Cultured human
keratinocytes
or mouse
embryo
ﬁbroblasts 3T3
cells
Viability measured by NR
uptake, morphology,
expression and release of
cytokines, skin physiology
Irritants and non-irritants. The
lack of a stratum corneum may
result in high sensitivity and over-
predict the irritation potential
Avoid poorly water-soluble chemicals Sanchez et al. (2006), Benavides et al.
(2004), Lee et al. (2000)
a Irritancy range and wording based on original references and does not include ECVAM and regulatory publications.
b Original references are cited.
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tation RHE assays may include additional endpoints such as cyto-
kine release e.g., IL-1a, a primary event in inﬂammation
(Williams and Kupper, 1996; Spielmann et al., 2007; Coquette
et al., 2003, 2005; Welss et al., 2004). Some protocols use short
incubation times of 4 h to mimic the in vivo human patch test (Tor-
nier et al., 2006), whereas others use longer times of 16 h (Faller
et al., 2002) and 42 h (Spielmann et al., 2007) which allow recovery
fromweak effects and advancement of signiﬁcant effects. There are
RHE models which have been developed using different combina-
tions of endpoints, namely EpiSkinTM, EpiDermTM, SkinEthicTM, Predi-
skinTM, LSE/HSE, Re-DED, Aligraf and Skin2 reviewed by Welss et al.
(2004), some of which are shown in Table 2.
Table 3 outlines the regulatory status of in vitro skin irritation
assays to detect corrosive and irritant chemicals. There are a num-
ber of validated in vitro assays to predict skin corrosivity and, to a
lesser extent, skin irritation. Whilst the models listed are mainly
used or validated for classiﬁcation and labelling purposes, they
can also be used as part of a safety assessment/benchmarking ap-
proach in consumer and occupational safety assessment. Currently,
the ESAC fully endorses three in vitro skin irritation models,
namely EpiSkinTM, EpiDermTM and SkinEthicTM as stand-alone
replacements for the Draize skin irritation test in animals. More-
over, these tests can be used as stand-alone tests to distinguish be-
tween skin irritating and non-irritating chemicals. The current
SCCP statement (SCCP, 2007) welcomes the use of the EpiSkinTM
model but still expresses concerns about the relevance of this test
to assess the skin irritation potential of cosmetics. The concerns
raised were twofold:
s The group of chemicals used to validate the assay, although
included a large number of cosmetic ingredients, only contained
one of the reference compounds listed in the Annexes to theDirective 76/768/EEC. The cosmetic industry has addressed this
concern by submitting EpiSkinTM data on over 20 cosmetic ingre-
dients included in the Annexes of the Cosmetics Directive. This
dataset conclusively shows that regulated cosmetic ingredients
belong to the application domain of the EpiskinTM test method,
and that predictive performance of this test is similar for such
ingredients and chemicals in general.
s Colouring chemicals that may interfere with the read-out sys-
tem (MTT assay) need to have additional controls in order to
take into account the non-speciﬁc optical density due to the
residual test substance colour. An industry report addressing
this issue has been submitted and is currently under review
by the SCCP/SCCS. It shows that such interferences are overall
infrequent and that when they occur, testing appropriate dilu-
tions of the colouring materials permit to reduce this unspeciﬁc
colouration to acceptable levels and to evaluate their skin irrita-
tion potential.2.3. Alternative approaches not yet validated and/or under
development
2.3.1. In vitro approaches
There are other in vitro skin irritationmodels which have not yet
been formally validated or received regulatory acceptance but have
proved useful in assessing the local tolerance of cosmetic ingredi-
ents using aWoE approach. Some of these are listed in Table 2, how-
ever, it is recognised that this list is not exhaustive. There are other
endpoints which are considered useful, such as IL-8 levels, lactate
dehydrogenase release and histological analysis (Welss et al., 2004).
2.3.2. In silico approaches
Computational models are available for Quantitative Structure
Activity Relationships ((Q)SAR), incorporating physicochemical
Table 3
Regulatory status of alternative skin corrosion and irritation assays.
Assay Validation organisation acceptance Regulatory acceptance Applicability as referenced by
authorities
On-going development to promote
external acceptance
Skin corrosion
Rat skin
transcutaneous
electrical resistance
(TER) test
ECVAM validation study in 1996–
1997 Fentem et al. (1998). ESAC
recommended that this assay be
used as a stand-alone replacement
for animal studies to identify
corrosive and non-corrosive
chemicals
Accepted by EU and US for the
prediction of the skin corrosion
potential OECD TG 430 (2004)
Corrosive and non-corrosive
chemicals. Not used to determine
degree (i.e., potency) of corrosives
Protocol currently being optimized
following ECVAM pre-validation
study to reduce FPs with
surfactants and neutral organics
In vitro reconstituted
human epidermal
(RHE) skin corrosion
models: EpiSkinTM,
EpiDermTM, EST1000
and SkinEthicTM
RHE models are accepted by ESAC
as validated assays to replace
animal skin corrosion studies
Regulatory accepted for the
prediction of the skin corrosion
potential, using MTT as the end
point (OECD protocol number
431, ESAC statement 21, March
2000)
Corrosive and non-corrosive
chemicals
Epidermal skin test
(EST1000) model
Recognised in the scientiﬁc
literature to have a good
in vitro:in vivo correlation, using
the twelve reference compounds
stipulated by the OECD TG 431
corrosivity protocol
Not accepted by regulatory
authorities for identifying skin
irritants
Corrosive and non-corrosive
chemicals
Needs a ‘‘catch-up validation” in
order to match the supporting data
available for the other models
Reconstituted
membrane barrier
test: the CorrositexTM
membrane barrier
test
The CorrositestTM model has been
endorsed by ESAC and adopted by
the OECD
Regulatory accepted for the
prediction of the skin corrosion
potential OECD TG 435, currently
under new draft discussions
CorrositestTM used as part of a
tiered strategy but only for the
determination of the corrosive
potential of speciﬁc chemicals
which cause a change in pH, such
as organic bases and inorganic
acids ESAC, (2000)
Skin irritation
EpiSkinTM In April, 2007, this model (using
MTT reduction and IL1a release)
was passed by ECVAM as a
validated alternative to the in vitro
irritation test
Accepted by EU for the
prediction of skin irritation
potential
R38 (label for skin irritation) and
non-irritating (no label) chemicals
The cosmetic industry submitting
EpiSkinTM data on over 20 cosmetic
ingredients included in the
Annexes of the Cosmetics
Directive. Experimental ﬁndings
on the effect of coloured chemicals
on the outcome of this model are
to be published
EpiDermTM In November, 2008, EpiDerm SIT
(using MTT reduction) was passed
by ECVAM as a validated
alternative to the in vitro irritation
test, following update validation
based on a modiﬁed protocol of
the validated EpiDerm model
(validated as part of a testing
strategy)
Accepted by EU for the
prediction of skin irritation
potential
R38 (label for skin irritation) and
non-irritating (no label) chemicals
SkinEthicTM RHE model In November, 2008, this model
(using MTT reduction) was passed
by ECVAM as a validated
alternative to the in vitro irritation
test
Accepted by EU for the
prediction of skin irritation
potential
R38 (label for skin irritation) and
non-irritating (no label) chemicals
Epidermal skin test
(EST1000) model
Not accepted by regulatory
authorities for identifying skin
irritants
Needs a ‘‘catch-up validation” in
order to match the supporting data
available for the other models
PrediSkin ECVAM pre-validation study
concluded that this method was
not ready to enter a formal
validation study. Protocol was
over-sensitive, resulting in the
prediction of all the non-irritant
chemicals as irritants Fentem et al.
(2001)
Not accepted by regulatory
authorities for identifying skin
irritants
Mouse skin integrity
function test (SIFT)
(ex-vivo)
Dropped from ECVAM validation
study due to low predictive power
Spielmann et al. (2007)
Not accepted by regulatory
authorities for identifying skin
irritants
Heylings et al. (2001, 2003),
Spielmann et al. (2007)
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chemicals (http://ecb.jrc.ec.europa.eu/documents/QSAR/QSAR_
Review_Irritation.pdf). (Q)SARs are theoretical models that predict
the ‘‘approximate relationship between a biological property of a
compound and its structure-derived physicochemical and struc-
tural properties” (Johnson and Maggiora, 1990). A decision supportsystem (DSS) developed by the German Federal Institute for Risk
Assessment (BfR) uses physicochemical exclusion rules to predict
the absence of skin irritation/corrosion potential in combination
with structural inclusion rules (SARs) to predict the presence of
such potential (Gerner et al., 2004a,b). The exclusion rules are
based on physicochemical properties such as molecular weight,
Table 4
In silico approaches used to predict skin irritation.
Application Description History
OECD (Q)SAR
Application
Toolbox
Incorporates information into a logical workﬂow by grouping chemicals
into chemical categories (www.oecd.org). Evaluates the hazard based on
the overall data set of the category, which must not have every chemical
tested for every end point. Read-across from one tested chemical to an
untested chemical is carried out to ﬁll the data gaps
The ﬁrst version was released in March 2008 and outlines the
technological proof-of-concept. Evaluation by RIVM 2005 Rorije and
Hulzebos (2005)
TOPKAT A statistically based system consisting of a number of robust, cross-
validated (Q)SAR models (www.accelrys.com) derived from large data
sets of toxicological information from the literature. Chemicals are
characterized according to structural, topologic, and electrotopologic
indices. This system contains models based on data from 1258
compounds (www.accelrys.com) and can differentiate between irritants
and non-irritants
A recent report demonstrated that TOPKAT performed well in predicting
the skin irritation potential of the majority of a panel of 116 test
chemicals Mombelli (2008)
DEREK A knowledge based system comprising a number of structural rules
(based on strongly acidic and basic features which relate to the parent
molecules) that aim to encode structure-toxicity information with an
emphasis on mechanisms
Vitic database
(Lhasa Ltd.)
A ‘chemically intelligent’ database which can recognise and search for
similarities in chemical structures
Decision support
system (DSS)
and (BfR)
The DSS SICRET (Skin Irritation Corrosion Rules Estimation Tool) model
consists of a number of rules (known as the Gerner rules) based on
physicochemical characteristics (such as melting point, logP and aqueous
solubility) to exclude irritation, and structural alerts to include and
predict corrosive chemicals (SICRET) and irritants Saliner et al. (2007)
This model correctly predicted 99.3% non-corrosives and 96.6% non-
irritants Saliner et al. (2007)
192 M. Macfarlane et al. / Regulatory Toxicology and Pharmacology 54 (2009) 188–196aqueous solubility, and log Kow, whereas the inclusion rules are
based on sub-structural molecular features. The physicochemical
rules implicitly take into account bioavailability (skin penetration)
whereas the structural rules take reactivity into account. The phys-
icochemical and structural rulebases are designed to predict the EU
risk phrases for skin irritation and skin corrosion. Further details
are given in QSAR Reporting Format for the BfR skin and eye irrita-Consideration of all av
data, e.g.:
Physicochemical prope
Literature /animal/in vitro
Read-across/SAR
skin corrosivity testi
Corrosive?
In vitro corrosivity t
(Table 1):
Corrosive?
In vitro skin irritation
(Table 2):
Irritant?
No
No
No
Non-irritant 
WoE strongly 
indicates 
chemical is not a 
skin irritant
Fig. 1. Decision tree approaches to evaluate ingredition rulebases. In one study focussing on esters (Smith et al., 2000),
the best variables correlating to human skin irritation were water
solubility (lower for irritants than non-irritants), a dispersion
parameter (higher for irritants), a hydrogen-bonding parameter
(higher for irritants), the sum of partial positive charges (lower
for irritants), and density (lower for irritants). There are a number
of in silico models available and these are outlined in Table 4. Dataailable 
rties
/human/
ng
est
 test
Yes
Yes
Corrosive
Irritant
Yes
ents and ﬁnal products for hazard assessment.
Neat ingredient 
No 
In vitro skin irritation: 
(in dilution)1 and/or 
formulation 
Irritant?
Non-irritant Irritant  Corrosive  
Consider confirmatory formulation test 
with human volunteers, e.g. patch test or other 
relevant in-use scenario test 
Yes 
Stop/risk reduction 
measures (e.g. labelling) 
relative to risk/benefit  
No 
In vitro corrosivity test:
(in dilution)1 and/or formulation 
Corrosive? 
at use concentration? 
Consider 
confirmatory 
product test to 
specify non versus 
mild/moderate 
irritancy  Comparing irritancy against benchmark control/ 
additional risk reduction 
measures (e.g. labelling) to 
reflect irritation potential or 
product reformulation 
Yes 
1 in vitro tests to further position use concentrations of chemicals in dilutions are not currently accepted by authorities 
Fig. 2. Decision tree approaches to evaluate ingredients and ﬁnal products for safety assessment based on hazard data for the neat ingredient.
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on the physicochemical properties of the ingredient to provide
information on its clinical tolerance. (Q)SARs might not constitute
a full replacement by themselves, but they are valuable tools for
screening and for prioritisation.
2.3.3. ‘‘Read-across” approach
The read-across approach uses the results obtained with a com-
pound to predict the outcome of the effect of a chemically-related
compound under evaluation. This may be based on chemical do-
main e.g., OECD Application Toolbox (www.oecd.org) or when ani-
mal data are available on similar substances. As with other end
points (such as eye irritation) such evaluations are only possible
when sufﬁcient historical in vivo data for the chemical domain
are available and there are no additional structural alerts that are
considered likely to cause corrosive or irritant effects.
3. A tiered approach for skin irritation assessment
The OECD TG 404 recommends the use of a stepwise approach
to evaluating the potential of a chemical to cause skin corrosion
and/or irritation (OECD TG 404, 2002). A decision tree strategy
for testing skin corrosion and irritation potential has been outlined
recently by Grindon et al. (2007). Similarly, we have constructed
two decision trees to aid approaches to using alternative models
for hazard assessment (Fig. 1) and safety assessment (Fig. 2) of irri-
tants. The decision trees can be used as a generic and broad over-
view of the type of questions needed to assess the potential hazard
and the actual safety at usage levels. It should be kept in mind that
it is not mandatory to carry out all the assays, rather they should be
a guide as to what issues should be addressed, which assays could
be used to resolve the issue and which extra assays could be used
to add weight to the assessment.3.1. Decision tree for hazard assessment
A decision tree for skin irritation hazard assessment is outlined
in Fig. 1. It should be noted that decisions in this tiered approach
take into account assays that already have regulatory acceptance
as well as those that are described in the scientiﬁc literature as
being suitable. This is a tiered approach using different steps:
Step 1: The initial step in hazard identiﬁcation is based on the
physicochemical properties (e.g., pH) and other available data
(e.g., (Q)SAR human and/or animal data) of the undiluted chem-
ical to answer the question ‘‘Does this chemical have the poten-
tial to be corrosive?”. A compound is considered corrosive if
indicated by the physicochemical properties. For example,
strong acids (pH 6 2) or bases (pHP 11.5) are considered cor-
rosive without the need for testing.
If the answer to this question is ‘‘yes”, the chemical is corrosive
and labelled accordingly (R34, similar to GHS Category 1). If the
answer to this question is ‘‘no”, proceed to Step 2. If the WoE
strongly indicates that the undiluted chemical is also not a skin
irritant, by-pass Step 2 and proceed to Step 3 (indicated by the
dotted lines).
Step 2: Conduct an in vitro corrosivity test to answer the ques-
tion ‘‘Is the corrosivity of the chemical conﬁrmed?”. Appropri-
ate assays accepted by regulatory authorities for the
identiﬁcation of non-corrosive chemicals and mixtures are
shown in Table 3. If the outcome of this assay indicates that
the chemical is corrosive, the labelling in Step 1 is conﬁrmed.
If the in vitro corrosivity test does not indicate corrosivity of
the chemical, proceed to Step 3.
Step 3: Conduct an in vitro assay for skin irritation to answer the
question ‘‘Is the chemical a skin irritant?”. Table 2 contains a list
of assays that have been developed to evaluate skin irritation.
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the skin irritant potential of a chemical is the in vitro EpiSkinTM
assay. If the outcome of assay(s) identiﬁes the chemical as an
irritant, it is labelled accordingly (irritant, R38, similar to GHS
Category 2). If the skin irritation test is negative, then the chem-
ical is non-irritating (no labelling/not classiﬁed (NC)).
3.2. Decision tree for safety assessment
A decision tree for safety assessment of chemicals using alterna-
tive skin irritation models is outlined in Fig. 2. At each step in
safety assessment, a WoE approach (based on physicochemical
properties and other available data) and read-across is recom-
mended. Following the outcome of the hazard identiﬁcation, there
are three possible outcomes for safety assessment, namely, corro-
sive, irritant and non-irritating.
If the chemical is corrosive: A tiered approach using different
steps is as follows:
Step 1: Conduct an in vitro corrosivity test using the relevant
concentration of the chemical to answer the question ‘‘Is the
chemical corrosive at the relevant concentrations?”.
If the answer to this question is ‘‘yes”, then the chemical is
not further considered for cosmetic use or can be further
tested in the intended formulation. If the outcome of the
formulation test for corrosivity is negative then proceed to
Step 2.
Step 2: Conduct an in vitro skin irritation test using the diluted
chemical and/or the ﬁnal formulation to ask the question ‘‘Is the
chemical an irritant at the relevant concentration?”.
If the answer to this question is ‘‘yes”, the chemical is an irri-
tant. Depending on comparison with benchmark controls the
decision can be made as to acceptability for market or re-for-
mulation of the product. If the outcome is negative the chemical
is not an irritant at relevant concentrations. Conﬁrmatory
human product testing can be considered to further specify
non versus mild/moderate skin irritancy (see below for non-
irritant scenario).
If the chemical is an irritant: follow Step 2 above.
If the chemical is non-irritant: Currently, it is not possible to dis-
tinguish a mild/moderate irritant from a non-irritant in vitro (de-
picted in Fig. 2 with dotted lines) and assess the whole severity
range of irritant responses of non-irritant chemicals. Therefore,
conﬁrmatory human product testing can be considered to further
specify non versus mild/moderate skin irritancy. This could be
patch testing or other appropriate in-use scenario test, considering
a stepwise approach to concentrations.4. Examples of the use of in vitro assays as part of the decision
tree approach
Numerous citations in the literature state a good correlation
between in vitro and clinical data. However, there is a regulatory
concern that the skin in vitro assays are under-predicting positive
responses. On the other hand there are reports that they might
actually over-predict responses (van de Sandt et al., 1999; Spiel-
mann et al., 2007). One positive aspect of a model that over-pre-
dicts a response is that there are likely to be fewer false negatives.
This was supported by the ECVAM validation study of the Epi-
SkinTM model, which predicted only a 1% frequency of false nega-
tives compared to 22.9% of false positives, based on the data set
generated in the evaluation (Spielmann et al., 2007). Importantly,
validated in vitro corrosivity and irritation tests using RHE skinmodels provide the same classiﬁcation information for ingredients
as the in vivo test. In-house validation studies of the SkinEthicTM
RHE model and the SkinEthicTM Oral Mucosal Model (Rowland
et al., 2003, 2007) have shown promising results. These models
are used routinely in-house to deliver clinical proof of principle
at the earliest opportunity. Data generated from these models
may be more clinically relevant than data derived from an animal
study or human skin patch test, since preclinical or clinical results
from these models are not always considered representative of
the intended application or use of certain products, particularly
in the instance of oral care applications. As a result of the conﬁ-
dence in the alternative models to predict skin irritation, they
are already used to assess the safety of chemicals in certain cases.
Other reasons for not using animal testing for safety assessment
include:
s When the assessment is on ﬁnished products, which is banned
(EU, 2003).
s When the chemical is anold ingredient forwhichdata are already
available. In these cases, a WoE approach can be adopted.
s For low concentrations of chemicals where an exposure-based
assessment can be done e.g., a TTC-like approach. This approach
is typically used for in-house assessments but the sharing of
data between companies should be encouraged.
s Where a WoE approach can be used based on:
s data from suppliers/literature and historical in vivo data;
s read-across from structurally similar chemicals with known
skin irritation potential or historical in vivo data (see Section
2.3.3);
s physicochemical properties indicating low potential for skin
irritancy;
s a documented history of safe use in relevant applications
and/or experience or use in other industries.s Where in vitro data compare with product formulations previ-
ously assessed as safe, plus a human test for conﬁrmation can
be used.
s Where other animal data are available (e.g., skin sensitization)
that could help in the safety assessment.5. Future needs
5.1. Regulatory acceptance of the EpiSkinTM, EpiDermTM and SkinEthicTM
models
The SCCP raised concerns about the applicability domain of the
validated in vitro EpiSkinTM model (SCCP, 2007), and these concerns
are currently being addressed. Acceptance by the SCCP of EpiSkinTM
data to predict the irritation potential of cosmetic ingredients can
therefore be anticipated and to date there have been no comments
on the other two models. In consideration of this point, the differ-
ence between qualiﬁcation and validation requires clariﬁcation.
Validation is needed for ECVAM approval as obtained for the Epi-
SkinTM model but qualiﬁcation may only be needed for in-house
veriﬁcation that an in vitro assay is predicting clinical outcomes
for the applied risk assessment purpose.
5.2. TTC-like approach
TTC-like approach refers to universal exposure thresholds of
chemical exposure below which there is a low probability of an
appreciable risk of skin irritation to humans (Kroes et al., 2004,
2007). It is a form of risk evaluation in which uncertainties based
from data on other compounds are balanced against the low level
of exposure (Munro et al., 2008). The use of this approach should
ideally be promoted and validated, especially for chemicals which
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sponse correlations are needed to interpret irritation potency. This
is because there may well be a threshold for this response, a fact
that is crucial for safety assessment.
5.3. Cumulative irritation assays
Current alternative models address only acute skin irritation
potential and not cumulative irritation potential. Cumulative irri-
tation is more important for many of the cosmetic-type ingredients
since the products tend to be used on a routine basis. However, the
development of in vitro models for chronic irritation is challenging
as it is not possible to culture/incubate cells for extended periods
(days or weeks). Researchers have been trying to design and vali-
date in vitro irritation assays to represent longer exposure periods
which are representative of longer (chronic) exposure or to reﬂect
exaggerated use (Rowland et al., 2003). The SkinEthicTM RHE model
has been used to compare irritation endpoints (modulation of cell
viability, the release and gene expression of IL-1a and IL-8, and
morphological changes) after a 72 h exposure period with irrita-
tion observed after 3 weeks in the clinical setting (de Brugerolle
de Fraissinette et al., 1999). There was a good correlation between
the in vitro and in vivo irritation potential, however, this model has
not been validated. Similarly the validation of other biomarkers of
irritation may need to be investigated, as reviewed by Welss et al.
(2004).
5.4. Exposure conditions
Extend the use of the in vitromethods to reﬂect the in vivo expo-
sure conditions (e.g., rinse-off conditions). Some current dosing
protocols include a rinse-off so that the reversibility of the irrita-
tion effect can be determined, for example, the validated EpiSkinTM
protocol. The question arises as to whether the ‘reversibility’ is cur-
rently assessed by in vitro models and whether they could be
adapted to do this. There may be differences of opinion as to
whether this could be achieved, although an ECVAM report by
van de Sandt et al. (1999) considered that one of the limitations
of in vitro models was an inability to assess recovery.6. Conclusions
Alternative models to the rabbit Draize test to detect skin irri-
tants have been developed and used in the cosmetics industry
for a number of years. The potential of a chemical to produce skin
corrosion can be evaluated using the validated rat skin TER assay
and the Human Skin Model Test (OECD TG 431, 2004) using Epi-
SkinTM, EpiDermTM and SkinEthicTM RHE models. For skin irritation,
EpiSkinTM, EpiDermTM and SkinEthicTM are validated as stand-alone
test replacements for the rabbit Draize test. One of the conclusions
from the COLIPA workshop of the COLIPA Project Team Safety
Assessment 2009/2013, was that the good correlation between
in vitro and in vivo skin irritation, together with the substantial
in-house experience of these assays has given conﬁdence in the
outcomes of these assays such that in-house safety assessments
on new products can be made without the use of animal testing.
Decision tree approaches incorporating alternative models for skin
corrosion and irritation can be used as a ﬂexible guide for safety
assessment, rather than a ‘tick-box’ approach. A decision tree for
hazard assessment and labelling, using a WoE approach through-
out, involves a step-wise evaluation of ﬁrstly, physicochemical
characteristics, (Q)SAR and existing data, to identify and rule out
corrosive chemicals for further testing; secondly, an in vitro corro-
sivity test; and ﬁnally, an in vitro irritation test to distinguish be-
tween irritants and non-irritants. Once a chemical has beenclassiﬁed as corrosive, irritant or a non-irritant, its safety assess-
ment can also be evaluated using a second decision tree approach.
Corrosive chemicals should be tested in an in vitro corrosivity test
at the use concentration and, if shown to be non-corrosive, tested
for irritation using an RHE in vitro irritation model. Chemicals la-
belled as irritants can be retested at the usage concentration, since
they may not be irritants at lower concentrations or when used in
the ﬁnal formulation. Human conﬁrmatory testing of the formula-
tion is only carried out on a case-by-case basis. Future goals in-
clude providing further validation data requested by the SCCP to
support their acceptance of EpiSkinTM; proposing additional work
on the TTC-like approach; extending in vitro models to include
exposure levels (rinse-off); and development of in vitro models to
reﬂect chronic exposure. In conclusion, the evaluation of the skin
irritation potential of new chemicals for use in cosmetics can be
conﬁdently accomplished using only alternative methods.References
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